Cargando…

Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark

Vaccination against human papillomavirus (HPV) has been introduced as a public health initiative in many countries, including Denmark since October 2008. It is important to monitor postimplementation effectiveness of HPV‐vaccination at the population‐level. We studied HPV‐prevalence after first invi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynge, Elsebeth, Thamsborg, Lise, Larsen, Lise Grupe, Christensen, Jette, Johansen, Tonje, Hariri, Jalil, Christiansen, Sanne, Rygaard, Carsten, Andersen, Berit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689747/
https://www.ncbi.nlm.nih.gov/pubmed/32542644
http://dx.doi.org/10.1002/ijc.33157
_version_ 1783613920327499776
author Lynge, Elsebeth
Thamsborg, Lise
Larsen, Lise Grupe
Christensen, Jette
Johansen, Tonje
Hariri, Jalil
Christiansen, Sanne
Rygaard, Carsten
Andersen, Berit
author_facet Lynge, Elsebeth
Thamsborg, Lise
Larsen, Lise Grupe
Christensen, Jette
Johansen, Tonje
Hariri, Jalil
Christiansen, Sanne
Rygaard, Carsten
Andersen, Berit
author_sort Lynge, Elsebeth
collection PubMed
description Vaccination against human papillomavirus (HPV) has been introduced as a public health initiative in many countries, including Denmark since October 2008. It is important to monitor postimplementation effectiveness of HPV‐vaccination at the population‐level. We studied HPV‐prevalence after first invitation to screening at age 23 years in women offered the quadrivalent HPV‐vaccine at the age of 14 years. Randomly selected screening samples from women born in 1994 in four out of five Danish regions were subjected to analysis for HPV in addition to routine cytology. Cobas4800 was used in all participating pathology departments. Data from a Danish prevaccination cross‐sectional study using Hybrid Capture 2, and a Danish split‐sample study using Cobas4800 were used for comparison. In the period from February 2017 to April 2019, 6233 screening samples from women born in 1994 were selected for HPV‐analysis; 27 samples had no HPV‐test and 3 samples had no HPV‐diagnosis, leaving 6203 samples with an HPV‐diagnosis. Prevalence of any high‐risk (HR) HPV was 35%; only 0.9% were positive for vaccine HPV types 16/18 while the remaining 34% were positive for other HR HPV. When comparing with prevaccination prevalence data, HPV‐16/18 decreased by 95%; RR = 0.05 (95% CI 0.04‐0.06), while other HR HPV remained fairly constant; RR = 0.88 (95% CI 0.82‐0.94) and RR = 0.95 (95% CI 0.88‐1.03), respectively. One‐third of women vaccinated as girls with the quadrivalent HPV‐vaccine were HR HPV‐positive at time of first invitation to screening. Vaccine HPV‐types 16 and 18 were almost eliminated, while the prevalence of nonvaccine HR HPV‐types remained constant.
format Online
Article
Text
id pubmed-7689747
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-76897472020-12-08 Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark Lynge, Elsebeth Thamsborg, Lise Larsen, Lise Grupe Christensen, Jette Johansen, Tonje Hariri, Jalil Christiansen, Sanne Rygaard, Carsten Andersen, Berit Int J Cancer Cancer Therapy and Prevention Vaccination against human papillomavirus (HPV) has been introduced as a public health initiative in many countries, including Denmark since October 2008. It is important to monitor postimplementation effectiveness of HPV‐vaccination at the population‐level. We studied HPV‐prevalence after first invitation to screening at age 23 years in women offered the quadrivalent HPV‐vaccine at the age of 14 years. Randomly selected screening samples from women born in 1994 in four out of five Danish regions were subjected to analysis for HPV in addition to routine cytology. Cobas4800 was used in all participating pathology departments. Data from a Danish prevaccination cross‐sectional study using Hybrid Capture 2, and a Danish split‐sample study using Cobas4800 were used for comparison. In the period from February 2017 to April 2019, 6233 screening samples from women born in 1994 were selected for HPV‐analysis; 27 samples had no HPV‐test and 3 samples had no HPV‐diagnosis, leaving 6203 samples with an HPV‐diagnosis. Prevalence of any high‐risk (HR) HPV was 35%; only 0.9% were positive for vaccine HPV types 16/18 while the remaining 34% were positive for other HR HPV. When comparing with prevaccination prevalence data, HPV‐16/18 decreased by 95%; RR = 0.05 (95% CI 0.04‐0.06), while other HR HPV remained fairly constant; RR = 0.88 (95% CI 0.82‐0.94) and RR = 0.95 (95% CI 0.88‐1.03), respectively. One‐third of women vaccinated as girls with the quadrivalent HPV‐vaccine were HR HPV‐positive at time of first invitation to screening. Vaccine HPV‐types 16 and 18 were almost eliminated, while the prevalence of nonvaccine HR HPV‐types remained constant. John Wiley & Sons, Inc. 2020-06-29 2020-12-15 /pmc/articles/PMC7689747/ /pubmed/32542644 http://dx.doi.org/10.1002/ijc.33157 Text en © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Cancer Therapy and Prevention
Lynge, Elsebeth
Thamsborg, Lise
Larsen, Lise Grupe
Christensen, Jette
Johansen, Tonje
Hariri, Jalil
Christiansen, Sanne
Rygaard, Carsten
Andersen, Berit
Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title_full Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title_fullStr Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title_full_unstemmed Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title_short Prevalence of high‐risk human papillomavirus after HPV‐vaccination in Denmark
title_sort prevalence of high‐risk human papillomavirus after hpv‐vaccination in denmark
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689747/
https://www.ncbi.nlm.nih.gov/pubmed/32542644
http://dx.doi.org/10.1002/ijc.33157
work_keys_str_mv AT lyngeelsebeth prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT thamsborglise prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT larsenlisegrupe prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT christensenjette prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT johansentonje prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT haririjalil prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT christiansensanne prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT rygaardcarsten prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark
AT andersenberit prevalenceofhighriskhumanpapillomavirusafterhpvvaccinationindenmark